Indian Journal of Endocrinology and Metabolism

ORIGINAL ARTICLE
Year
: 2011  |  Volume : 15  |  Issue : 5  |  Page : 33--39

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes


Karuna Balwant Ramteke1, Sunita Jaiprakash Ramanand1, Jaiprakash B Ramanand2, Suyog Subhash Jain1, Girish Tulsidas Raparti1, Milind Hari Patwardhan3, Mangala Murthy1, Ravi G Ghanghas1 
1 Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India
2 Department of Pharmacology, R.C.S.M. Government Medical College, Kolhapur, Maharashtra, India
3 Director, Patwardhan Endocrinology Hospital and Research Centre, Miraj, Maharashtra, India

Correspondence Address:
Karuna Balwant Ramteke
Department of Pharmacology, Government Medical College, Miraj, Maharashtra
India

Context: Diabetes mellitus is a chronic metabolic disorder of endocrinal origin with multiorgan involement. Today«SQ»s physician has a lot many options to choose for treating type 2 diabetes, but does not always manages to achieve optimal glycemic control. The newer drug bromocriptine acts by novel hypothalamic circadian rhythm resetting mechanism. Objective: To evaluate the efficacy and safety of bromocriptine QR in type 2 diabetes. Materials and Methods: 105 patients according to inclusion and exclusion criteria were randomized into three groups by simple randomization. Group 1 received bromocriprine 2.4 mg once daily, group 2 received metformin 500 mg twice daily while group 3 received bromocriprine 1.6 mg daily and metformin 500 mg twice daily. Baseline measurement of fasting and postprandial blood sugar, HbA1 C and BMI were followed up at 6 th and 12 th weeks. Safety evaluation was done by questioning the patient and also through routine hematological and biochemical parameters. Z test was used for analysis. Results: Group 1 showed significant reduction in fasting and postprandial sugar and HbA 1c at 12 weeks. While groups 2 and 3 showed even higher reduction in these parameters albeit with slightly more adverse drug events like nausea, vomiting compared to group 1. Conclusion: Bromocriptine QR is an effective and safe antidiabetic drug which can be employed as monotherapy or in conjuction with metformin to achieve and maintain optimal glycemic control.


How to cite this article:
Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, Murthy M, Ghanghas RG. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes.Indian J Endocr Metab 2011;15:33-39


How to cite this URL:
Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, Murthy M, Ghanghas RG. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocr Metab [serial online] 2011 [cited 2021 Apr 12 ];15:33-39
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=5;spage=33;epage=39;aulast=Ramteke;type=0